An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options

NCT00042393 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2014-01-07

No results posted yet for this study

Summary

The purpose of this early access protocol is to provide access to adefovir dipivoxil prior to its commercial availability to people with lamivudine-resistant chronic hepatitis B who have limited treatment options.

Conditions

Interventions

DRUG

Adefovir Dipivoxil

Sponsors & Collaborators

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00042393 on ClinicalTrials.gov